Lesinurad是URAT1(尿酸转运蛋白1)与OAT(有机阴离子转运体)抑制剂，同时还是肾转运蛋白OAT1和OAT3的底物，它也是一种选择性尿酸重吸收抑制剂。该药常与黄嘌呤氧化酶抑制剂联用，用于治疗痛风相关的高尿酸血症。
| 英文别名 (English Synonym) | Lesinurad |
| 中文名称 (Chinese Name) | 雷西那德 |
| 靶点 (Target) | URAT1 |
| 通路 (Pathway) | Membrane Transporter/Ion Channel |
| CAS号 (CAS NO.) | 878672-00-5 |
| 分子式 (Formula) | C17H14BrN3O2S |
| 分子量 (Molecular Weight) | 404.28 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Jin H, Zhang MY, Qu OY, Wang ZY, Salmon DP, Katzman R, Grant I, Liu WT, Yu ES. Cross-cultural studies of dementia: use of a Chinese version of the Blessed-Roth Information-Memory-Concentration test in a Shanghai dementia survey. Psychol Aging. 1989 Dec;4(4):471-9. doi: 10.1037//0882-7974.4.4.471. PMID: 2695120.[2]Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. doi: 10.1177/1759720X16646703. Epub 2016 May 2. PMID: 27493693; PMCID: PMC4959626.[3]Yeh, Litain & Yang, Jennifer & Theiss, Jeff & Zhou, Dongmei & Yan, Rongzi & Borges, Virginia & Nguyen, Mai & Tieu, Kathy & Manhard, Kimberly & Quart, Barry. (2008). RDEA594, a potential uric acid lowering agent through inhibition of uric acid reuptake, shows better pharmacokinetics than its prodrug RDEA806. S178-S178.
